Preventing and Treating Brain Metastases with Three First-Line EGFR-TKI in Patients with EGFR Mutation Advanced NSCLC

被引：0
|
作者：
Lin, C. [1 ]
Su, W. [1 ]
Wu, Y. [2 ]
机构：
[1] Natl Cheng Kung Univ Hosp, Dept Internal Med, Tainan, Taiwan
[2] Natl Cheng Kung Univ Hosp, Dept Nursing, Tainan, Taiwan
来源：
JOURNAL OF THORACIC ONCOLOGY | 2018年 / 13卷 / 10期
关键词：
Brain metastasis; tyrosine kinase inhibitor; EGFR mutation;
D O I：
10.1016/j.jtho.2018.08.616
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P1.01-60
引用
收藏
页码：S484 / S484
页数：1
相关论文
共 50 条
  • [21] Carboplatin and Pemetrexed Plus Bevacizumab After Failure of First-Line EGFR-TKI Therapy for NSCLC Harboring EGFR Mutation (CJLSG 0908)
    Goto, Y.
    Takahashi, K.
    Saito, H.
    Ogasawara, T.
    Shindoh, J.
    Kimura, T.
    Sugino, Y.
    Kojima, E.
    Nomura, F.
    Nakanishi, T.
    Nozaki, Y.
    Takeyama, Y.
    Imaizumi, K.
    Hasegawa, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S469 - S470
  • [22] Chemotherapy Plus EGFR-TKI as First-Line Treatment Provides Better Survival for EGFR Mutation NSCLC Patients: Update Data for NCT02148380
    Zhang, W.
    Xu, J.
    Lou, Y.
    Zhang, Y.
    Han, B.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S236 - S236
  • [23] Factors affecting PS deterioration at the time of relapse after the first-line EGFR-TKI therapy in EGFR-mutant advanced NSCLC
    Tamura, Tomoki
    Hotta, Katsuyuki
    Gotoda, Hiroko
    Kato, Yuka
    Ichihara, Eiki
    Kubo, Toshio
    Tanimoto, Mltsune
    Kiura, Katsuyuki
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [24] Comparing EGFR-TKI with EGFR-TKI plus Chemotherapy as 1st Line Treatment in Advanced NSCLC Patients with Both Mutated EGFR and Bim Polymorphism
    He, Y.
    Zhao, C.
    Li, X.
    Ren, S.
    Jiang, T.
    Zhang, J.
    Su, C.
    Chen, X.
    Cai, W.
    Gao, G.
    Li, W.
    Wu, F.
    Li, J.
    Zhao, J.
    Zhou, F.
    Hu, Q.
    Hirsch, F. R.
    Zhou, C.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1970 - S1970
  • [25] Liver Metastases Is the Negative Predictive Factor for First-Line EGFR TKIs Therapy in NSCLC Patients with EGFR Mutation
    Jiang, Tao
    Zhou, Caicun
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1246 - S1247
  • [26] Osimertinib vs SoC EGFR-TKI as First-Line Treatment in Patients with EGFRm Advanced NSCLC (FLAURA): Plasma ctDNA Analysis
    Gray, J.
    Okamoto, I.
    Sriuranpong, V.
    Vansteenkiste, J.
    Imamura, F.
    Lee, J. S.
    Pang, Y.
    Cobo, M.
    Kasahara, K.
    Hodge, R.
    Lentrichia, B.
    Dearden, S.
    Ramalingam, S.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1754 - S1755
  • [27] WHICH DO PATIENTS PREFER AS A FIRST-LINE THERAPY, EGFR-TKI OR CHEMOTHERAPY, IF THEY HAVE NSCLC HARBORING EGFR MUTATION? A VIGNETTES STUDY (LOGIK0903).
    Ebi, Noriyuki
    Suetsugu, Takayuki
    Fukuda, Minoru
    Nagata, Nobuhiko
    Takayama, Koichi
    Tsuruta, Nobuko
    Ishida, Masayuki
    Nishida, Chinatsu
    Kashiwabara, Kosuke
    Akamine, Shinji
    Komiya, Kazutoshi
    Nakagaki, Noriaki
    Kishi, Hiroto
    Tokunaga, Shoji
    Sasaki, Jiichiro
    Ichinose, Yukito
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S1160 - S1161
  • [28] Which do patients prefer as a first-line therapy, EGFR-TKI or chemotherapy, if they have NSCLC harboring EGFR mutation? A Vignettes study (LOGIK0903).
    Sasaki, Jiichiro
    Tokunaga, Shoji
    Suetsugu, Takayuki
    Ebi, Noriyuki
    Fukuda, Minoru
    Nagata, Nobuhiko
    Takayama, Koichi
    Tsuruta, Nobuko
    Ishida, Masayuki
    Nishida, Chinatsu
    Kashiwabara, Kosuke
    Akamine, Shinji
    Komiya, Kazutoshi
    Nakagaki, Noriaki
    Kishi, Hiroto
    Seto, Takashi
    Saeki, Sho
    Uchitomi, Yosuke
    Ichinose, Yukito
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [29] Osimertinib vs standard of care (SoC) EGFR-TKI as first-line therapy in patients (pts) with EGFRm advanced NSCLC: FLAURA
    Ramalingam, S.
    Reungwetwattana, T.
    Chewaskulyong, B.
    Dechaphunkul, A.
    Lee, K. H.
    Imamura, F.
    Nogami, N.
    Ohe, Y.
    Cheng, Y.
    Cho, B. C.
    Cho, E. K.
    Vansteenkiste, J. F.
    Voon, P. J.
    Zhou, C.
    Gray, J.
    Hodge, R.
    Rukazenkov, Y.
    Soria, J-C.
    ANNALS OF ONCOLOGY, 2017, 28
  • [30] Osimertinib vs standard of care (SoC) EGFR-TKI as first-line treatment in patients with EGFR-TKI sensitising mutation (EGFRm) positive advanced non-small cell lung cancer (NSCLC): FLAURA Asian subset
    Cho, B. C.
    Chewaskulyong, B.
    Lee, K. H.
    Dechaphunkul, A.
    Sriuranpong, V.
    Imamura, F.
    Ohe, Y.
    Nogami, N.
    Kurata, T.
    Okamoto, I.
    Zhou, C.
    Cheng, Y.
    Cho, E. K.
    Jye, V. P.
    Lee, J-S.
    Mann, H.
    Saggese, M.
    Reungwetwattana, T.
    ANNALS OF ONCOLOGY, 2017, 28 : 190 - 190
12345